AIMS: Patients with structural heart disease (SHD) undergoing catheter ablation (CA) for ventricular tachycardia (VT) are at considerable risk of periprocedural complications, including acute haemodynamic decompensation (AHD). The PAINESD score was proposed to predict the risk of AHD. The goal of this study was to validate the PAINESD score using the retrospective analysis of data from a large-volume heart centre. METHODS AND RESULTS: Patients who had their first radiofrequency CA for SHD-related VT between August 2006 and December 2020 were included in the study. Procedures were mainly performed under conscious sedation. Substrate mapping/ablation was performed primarily during spontaneous rhythm or right ventricular pacing. A purposely established institutional registry for complications of invasive procedures was used to collect all periprocedural complications that were subsequently adjudicated using the source medical records. Acute haemodynamic decompensation triggered by CA procedure was defined as intraprocedural or early post-procedural (<12 h) development of acute pulmonary oedema or refractory hypotension requiring urgent intervention. The study cohort consisted of 1124 patients (age, 63 ± 13 years; males, 87%; ischaemic cardiomyopathy, 67%; electrical storm, 25%; New York Heart Association Class, 2.0 ± 1.0; left ventricular ejection fraction, 34 ± 12%; diabetes mellitus, 31%; chronic obstructive pulmonary disease, 12%). Their PAINESD score was 11.4 ± 6.6 (median, 12; interquartile range, 6-17). Acute haemodynamic decompensation complicated the CA procedure in 13/1124 = 1.2% patients and was not predicted by PAINESD score with AHD rates of 0.3, 1.8, and 1.1% in subgroups by previously published PAINESD terciles (<9, 9-14, and >14). However, the PAINESD score strongly predicted mortality during the follow-up. CONCLUSION: Primarily substrate-based CA of SHD-related VT performed under conscious sedation is associated with a substantially lower rate of AHD than previously reported. The PAINESD score did not predict these events. The application of the PAINESD score to the selection of patients for pre-emptive mechanical circulatory support should be reconsidered.
- MeSH
- Hemodynamics * MeSH
- Hypotension etiology physiopathology diagnosis MeSH
- Cicatrix physiopathology MeSH
- Catheter Ablation * adverse effects MeSH
- Tachycardia, Ventricular * surgery physiopathology etiology diagnosis MeSH
- Middle Aged MeSH
- Humans MeSH
- Pulmonary Edema etiology diagnosis physiopathology MeSH
- Postoperative Complications etiology diagnosis MeSH
- Retrospective Studies MeSH
- Risk Factors MeSH
- Aged MeSH
- Check Tag
- Middle Aged MeSH
- Humans MeSH
- Male MeSH
- Aged MeSH
- Female MeSH
- Publication type
- Journal Article MeSH
- Keywords
- elektrická bouře,
- MeSH
- Amiodarone therapeutic use MeSH
- Adrenergic beta-Antagonists therapeutic use MeSH
- Defibrillators, Implantable MeSH
- Ventricular Fibrillation diagnosis ethnology MeSH
- Angiotensin-Converting Enzyme Inhibitors therapeutic use MeSH
- Catheter Ablation methods MeSH
- Tachycardia, Ventricular etiology MeSH
- Ventricular Premature Complexes etiology MeSH
- Humans MeSH
- Arrhythmias, Cardiac * diagnosis drug therapy pathology MeSH
- Heart Failure * complications MeSH
- Accelerated Idioventricular Rhythm etiology MeSH
- Check Tag
- Humans MeSH
- Publication type
- Review MeSH
BACKGROUND AND PURPOSE: Saline-irrigated radiofrequency ablation (RFA) for atrial fibrillation (AF) is limited by the absence of reliable thermal feedback limiting the utility of temperature monitoring for power titration. The DiamondTemp (DT) ablation catheter was designed to allow efficient temperature-controlled irrigated ablation. We sought to assess the 1-year clinical safety and efficacy of the DT catheter in treating drug-refractory paroxysmal AF. METHODS: The TRAC-AF trial (NCT02821351) is a prospective, multi-center (n = 4), single-arm study which enrolled patients with symptomatic, drug-refractory, paroxysmal AF. Using the DT catheter, point-by-point ablation was performed around all pulmonary veins (PVs) to achieve PV isolation (PVI). Ablation was performed in a temperature-controlled mode (60 °C, max 50 W). Acute and chronic efficacy and safety was evaluated. RESULTS: Seventy-one patients (age 69.9 ± 11.0 years; 60.6% male) were ablated using the DT catheter. The mean fluoroscopy and RF ablation times were 9.3 ± 6.1 min and 20.6 ± 8.9 min, respectively. Acute isolation of all PVs was achieved in 100% of patients, and freedom from AF after 1 year was 70.6%. There were no steam pops, char, or coagulum on the catheter tip after ablation. There were few serious procedure/device-related adverse events including a single case of cardiac tamponade (1.4%) and transient ischemic attack (1.4). CONCLUSION: This first in man series demonstrates that temperature-controlled irrigated RFA with the DT catheter is efficient, safe, and effective in the treatment of paroxysmal AF. Randomized controlled trials are ongoing and will evaluate better the role of this catheter in relation to standard RFA. TRIAL REGISTRATION: Registered on the site ClinicalTrials.gov January 2016 with identifier: NCT02821351.
- MeSH
- Equipment Design MeSH
- Atrial Fibrillation * MeSH
- Catheter Ablation * adverse effects MeSH
- Middle Aged MeSH
- Humans MeSH
- Prospective Studies MeSH
- Aged, 80 and over MeSH
- Aged MeSH
- Temperature MeSH
- Pulmonary Veins * surgery MeSH
- Treatment Outcome MeSH
- Check Tag
- Middle Aged MeSH
- Humans MeSH
- Male MeSH
- Aged, 80 and over MeSH
- Aged MeSH
- Female MeSH
- Publication type
- Journal Article MeSH
- Clinical Trial MeSH
- Multicenter Study MeSH
PURPOSE: Durable pulmonary vein (PV) isolation (PVI) determines the clinical success of catheter ablation for atrial fibrillation. In this randomized study, we investigated whether the temporally discontiguous deployment of ablation lesions adversely affected the acute efficacy of PVI. METHODS: Thirty-six consecutive patients with drug-refractory paroxysmal atrial fibrillation (aged 59 ± 11, 58% males) were randomized 1:1 to either discontiguous (D-PVI) or contiguous (C-PVI) encircling radiofrequency (RF) lesions around ipsilateral PVs. A contact force-sensing catheter was used targeting a final interlesion distance < 6 mm and the ablation index of 400-450 (anterior wall) and 300-350 (posterior wall). The study endpoint was defined as failure of first-pass PVI or acute PV reconnection during a waiting time (> 30 min) followed by adenosine challenge. RESULTS: The total RF time, number of RF lesions, and mean interlesion distance were comparable in both groups. Total endpoint rates were 1/36 (3%) in the D-PVI vs 4/36 (11%) in the C-PVI groups; P = 0.34 for superiority, P = 0.008 for non-inferiority. Adenosine-induced reconnection of right PVs was the only endpoint in the D-PVI group. In the C-PVI group, first-pass PVI failed in 2 right PVs and spontaneous reconnection occurred in 2 other circles (left and right PVs). CONCLUSION: Temporally discontiguous deployment of RF lesions is not associated with lower procedural PVI efficacy when strict criteria for interlesion distance and ablation index are applied. The development of local edema around each ablation site does not prevent effective RF lesion formation at adjacent positions. TRIAL REGISTRATION: clinicaltrials.gov (NCT03332862).
- MeSH
- Adenosine MeSH
- Atrial Fibrillation * surgery MeSH
- Catheter Ablation * MeSH
- Humans MeSH
- Recurrence MeSH
- Pulmonary Veins * surgery MeSH
- Treatment Outcome MeSH
- Check Tag
- Humans MeSH
- Male MeSH
- Female MeSH
- Publication type
- Journal Article MeSH
- Randomized Controlled Trial MeSH
AIMS: Catheter ablation of ventricular tachycardia (VT) is an effective treatment in patients with structural heart disease (SHD) and recurrent arrhythmias. However, the procedure is associated with the risk of complications, including both manifest and asymptomatic cerebral thromboembolic events. We hypothesized that periprocedural asymptomatic brain injury (ABI) can be reduced by using transseptal instead of the retrograde access route to the left ventricle (LV). METHODS AND RESULTS: Consecutive patients undergoing VT ablation for SHD were randomized 1:1 to either retrograde or transseptal LV access. All patients underwent radiofrequency ablation in conscious sedation with the use of an irrigated tip catheter. The degree of brain damage was evaluated by serum level of biomarker S100B. Significant ABI was defined as a post-ablation relative increase of S100B level >30%. A total of 144 patients (66 ± 9 years; 14 females; 90% coronary artery disease; LV ejection fraction: 30 ± 8%) were enrolled and 72 were allocated to each study groups. Symptomatic neurological complication of the procedure was not observed in any subject. A significant ABI was detected in 19.4% of patients. It was more commonly observed in subjects randomized to retrograde vs. transseptal LV access (26.4% vs. 12.5%, P = 0.04). In a multivariate analysis, only retrograde LV access and advanced age were independent determinants of significant ABI. CONCLUSION: Significant ABI after ablation of VT in patients with SHD can be detected in one-fifth of subjects. Retrograde access to LV is associated with a two-fold higher probability of significant ABI.
- MeSH
- Catheter Ablation * adverse effects MeSH
- Tachycardia, Ventricular * diagnosis surgery MeSH
- Middle Aged MeSH
- Humans MeSH
- Heart Diseases * MeSH
- Brain Injuries * MeSH
- Aged MeSH
- Heart Ventricles MeSH
- Treatment Outcome MeSH
- Check Tag
- Middle Aged MeSH
- Humans MeSH
- Male MeSH
- Aged MeSH
- Female MeSH
- Publication type
- Journal Article MeSH
- Randomized Controlled Trial MeSH
INTRODUCTION: Frequent ventricular premature complexes (VPCs) may cause symptoms and/or lead to deterioration of LV systolic function. Although frequent VPCs may be abolished by catheter ablation, it may be challenging in case of their origin from the LV papillary muscles (PMs). Our collaborative study aimed to analyze in detail the site of origin and the outcome of ablation. METHODS: Consecutive 34 patients (males: 68%; aged 62 ± 12 years; LV ejection fraction: 50 ± 9%) undergoing catheter ablation of VPCs originating from PMs were included. All procedures were guided by intracardiac echocardiography. RESULTS: The size and shape of PMs were highly variable. The length of anterolateral and posteromedial PM was 23 ± 4 mm and 28 ± 7 mm, respectively. In about one-third of patients, the PM was formed by two distinctly separate heads. The ectopic foci were located on anterolateral, posteromedial or both PM in 35%, 56% and 9% of cases, respectively. Their location was found within the distal, mid, or proximal (basal) third of PM in the 67%, 19%, and 14%, respectively. A total of 86% of PM foci were acutely abolished and long-term success was achieved in 65% of patients. Absence of VPCs of other morphologies and a high burden of ectopic activity before ablation were associated with favorable clinical outcome. CONCLUSION: VPCs originate predominantly from the distal portion of the PM. This knowledge may facilitate the mapping in patients with infrequent ectopic beats. Intracardiac echocardiography is of crucial importance for navigation of the ablation catheter and for assessment of its stability at PM target sites.
- MeSH
- Action Potentials MeSH
- Time Factors MeSH
- Echocardiography MeSH
- Electrophysiologic Techniques, Cardiac MeSH
- Ventricular Function, Left * MeSH
- Catheter Ablation MeSH
- Ventricular Premature Complexes diagnosis physiopathology surgery MeSH
- Middle Aged MeSH
- Humans MeSH
- Papillary Muscles diagnostic imaging physiopathology surgery MeSH
- Aged MeSH
- Heart Rate * MeSH
- Heart Ventricles diagnostic imaging physiopathology surgery MeSH
- Check Tag
- Middle Aged MeSH
- Humans MeSH
- Male MeSH
- Aged MeSH
- Female MeSH
- Publication type
- Journal Article MeSH
- Multicenter Study MeSH
- Geographicals
- Europe MeSH
Aims: Complications of catheter ablation for atrial fibrillation (AF) are frequently related to vascular access. We hypothesized that ultrasound-guided (USG) venipuncture may facilitate the procedure and reduce complication rates. Methods and results: We conducted a multicentre, randomized trial in patients undergoing catheter ablation for AF on uninterrupted anticoagulation therapy. The study enrolled consecutive 320 patients (age: 63 ± 8 years; male: 62%) and were randomized to USG or conventional venipuncture in 1:1 fashion. It was prematurely terminated due to substantially lower-than-expected complication rates, which doubled the population size needed to maintain statistical power. While the complication rates did not differ between two study arms (0.6% vs. 1.9%, P = 0.62), intra-procedural outcome measures were in favour of the USG approach (puncture time, 288 vs. 369 s, P < 0.001; first pass success, 74% vs. 20%, P < 0.001; extra puncture attempts 0.5 vs. 2.1, P < 0.001; inadvertent arterial puncture 0.07 vs. 0.25, P < 0.001; unsuccessful cannulation 0.6% vs. 14%, P < 0.001). Though these measures varied between trainees (49% of procedures) and expert operators, between-arm differences (except for unsuccessful cannulation) were comparably significant in favour of USG approach for both subgroups. Conclusions: Ultrasound-guided puncture of femoral veins was associated with preferable intra-procedural outcomes, though the major complication rates were not reduced. Both trainees and expert operators benefited from the USG strategy. (www.clinicaltrials.gov ID: NCT02834221).
- MeSH
- Time Factors MeSH
- Atrial Fibrillation diagnosis physiopathology surgery MeSH
- Ultrasonography, Interventional * MeSH
- Catheter Ablation * adverse effects MeSH
- Middle Aged MeSH
- Humans MeSH
- Catheterization, Peripheral adverse effects methods MeSH
- Postoperative Complications etiology MeSH
- Early Termination of Clinical Trials MeSH
- Punctures MeSH
- Risk Factors MeSH
- Aged MeSH
- Femoral Vein diagnostic imaging MeSH
- Treatment Outcome MeSH
- Check Tag
- Middle Aged MeSH
- Humans MeSH
- Male MeSH
- Aged MeSH
- Female MeSH
- Publication type
- Journal Article MeSH
- Multicenter Study MeSH
- Randomized Controlled Trial MeSH
- Comparative Study MeSH
- Geographicals
- Czech Republic MeSH
- Japan MeSH
- MeSH
- Tachycardia, Atrioventricular Nodal Reentry diagnosis physiopathology therapy MeSH
- Diagnosis, Differential MeSH
- Atrial Flutter diagnosis classification therapy MeSH
- Humans MeSH
- Tachycardia, Sinus diagnosis etiology physiopathology therapy MeSH
- Tachycardia, Supraventricular * diagnosis classification therapy MeSH
- Check Tag
- Humans MeSH
- Publication type
- Review MeSH
Vedení antikoagulační léčby v perioperačním období je mnohdy náročným úkolem, který vyžaduje posouzení vztahu mezi tromboembolickým rizikem a rizikem krvácení vyplývajícím ze samotného chirurgického výkonu. Výsledky z velkých randomizovaných studií, které se zabývaly optimálním perioperačním režimem, jsou omezené. Tento přehledový článek shrnuje současné dostupné poznatky o péči o pacienty užívající antikoagulancia v perioperačním období. Zároveň článek uvádí praktický postup optimální perioperační strategie u této skupiny pacientů.
The management of anticoagulation therapy in peri-operative setting is a common problem, because of required balancing between thromboembolic risk and hemorrhagic risk arising from surgery. Evidence from randomized studies regarding the optimal peri-operative approach is lacking. This review summarizes the available evidence for peri-operative management in patients on anticoagulation therapy. At the same time presents a practical approach for optimal peri-operative strategy in this group of patients.
- MeSH
- Anticoagulants * administration & dosage adverse effects therapeutic use MeSH
- Surgical Procedures, Operative methods utilization MeSH
- Atrial Fibrillation MeSH
- Heparin, Low-Molecular-Weight administration & dosage adverse effects therapeutic use MeSH
- Heparin administration & dosage adverse effects therapeutic use MeSH
- Comorbidity MeSH
- Humans MeSH
- Meta-Analysis as Topic MeSH
- Perioperative Care * methods trends utilization MeSH
- Postoperative Hemorrhage prevention & control therapy MeSH
- Risk Factors MeSH
- Statistics as Topic MeSH
- Thromboembolism * prevention & control MeSH
- Age Factors MeSH
- Warfarin administration & dosage adverse effects therapeutic use MeSH
- Venous Thrombosis MeSH
- Check Tag
- Humans MeSH
- Publication type
- Review MeSH
